These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29145215)

  • 21. Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12-17 Years.
    Danne T; Biester T; Kapitzke K; Jacobsen SH; Jacobsen LV; Petri KCC; Hale PM; Kordonouri O
    J Pediatr; 2017 Feb; 181():146-153.e3. PubMed ID: 27979579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program.
    Steinberg WM; Rosenstock J; Wadden TA; Donsmark M; Jensen CB; DeVries JH
    Diabetes Care; 2017 Jul; 40(7):839-848. PubMed ID: 28473337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial.
    Lewin AJ; Weir MR
    Clin Ther; 2008 Dec; 30(12):2354-65. PubMed ID: 19167594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacotherapy for obesity].
    Bruun JM
    Ugeskr Laeger; 2016 Oct; 178(44):. PubMed ID: 27808050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).
    Buse JB; Vilsbøll T; Thurman J; Blevins TC; Langbakke IH; Bøttcher SG; Rodbard HW;
    Diabetes Care; 2014 Nov; 37(11):2926-33. PubMed ID: 25114296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers.
    Fujioka K; O'Neil PM; Davies M; Greenway F; C W Lau D; Claudius B; Skjøth TV; Bjørn Jensen C; P H Wilding J
    Obesity (Silver Spring); 2016 Nov; 24(11):2278-2288. PubMed ID: 27804269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study.
    Irie S; Matsumura Y; Zdravkovic M; Jacobsen LV; Kageyama S
    Int J Clin Pharmacol Ther; 2008 Jun; 46(6):273-9. PubMed ID: 18541123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis.
    Zhang P; Liu Y; Ren Y; Bai J; Zhang G; Cui Y
    Afr Health Sci; 2019 Sep; 19(3):2591-2599. PubMed ID: 32127832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial.
    Hegedüs L; Sherman SI; Tuttle RM; von Scholten BJ; Rasmussen S; Karsbøl JD; Daniels GH;
    Diabetes Care; 2018 Mar; 41(3):620-622. PubMed ID: 29279300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvements in health-related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity.
    Kolotkin RL; Gabriel Smolarz B; Meincke HH; Fujioka K
    Clin Obes; 2018 Feb; 8(1):1-10. PubMed ID: 29045079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial.
    Wadden TA; Tronieri JS; Sugimoto D; Lund MT; Auerbach P; Jensen C; Rubino D
    Obesity (Silver Spring); 2020 Mar; 28(3):529-536. PubMed ID: 32090517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liraglutide 3.0 mg in the treatment of adults with obesity and prediabetes using real-world UK data: A clinical evaluation of a multi-ethnic population.
    Dobbie LJ; Coelho C; Mgaieth F; Chauhan K; Campbell S; Shuriye S; Hollington J; Appleton S; Sen Gupta P; Duncan A; McGowan B
    Clin Obes; 2024 Jun; 14(3):e12649. PubMed ID: 38438339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liraglutide preserves renal function in overweight diabetic patients with stage 3 chronic kidney disease.
    de Lucas MDG; Bueno BA; Sierra JO
    Eur J Intern Med; 2017 Oct; 44():e28-e29. PubMed ID: 28711390
    [No Abstract]   [Full Text] [Related]  

  • 34. A randomized controlled trial investigating the effect of liraglutide on self-reported liking and neural responses to food stimuli in participants with obesity.
    Coppin G; Muñoz Tord D; Pool ER; Locatelli L; Achaibou A; Erdemli A; León Pérez L; Wuensch L; Cereghetti D; Golay A; Sander D; Pataky Z
    Int J Obes (Lond); 2023 Dec; 47(12):1224-1231. PubMed ID: 37626125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Dietary Self-Monitoring, Physical Activity, Liraglutide 3.0 mg, and Placebo on Weight Loss in the SCALE IBT Trial.
    Tronieri JS; Fabricatore AN; Wadden TA; Auerbach P; Endahl L; Sugimoto D; Rubino D
    Obes Facts; 2020; 13(6):572-583. PubMed ID: 33197917
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Weight loss and treatment patterns in a real-world population of adults receiving liraglutide 3.0 mg for weight management in routine clinical practice in Switzerland (ADDRESS study).
    Schultes B; Timper K; Cavadini G; Rüh J; Gerber PA
    Diabetes Obes Metab; 2024 Mar; 26(3):1023-1032. PubMed ID: 38092710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The importance of relationship processes for lowering BMI over time in women with type 2 diabetes in a randomized controlled trial.
    Yorgason JB; Sandberg JG; Weinstock RS; Trief PM; Fisher L; Hessler D
    Obes Res Clin Pract; 2019; 13(6):599-601. PubMed ID: 31653476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real-world effectiveness study in Canada.
    Wharton S; Haase CL; Kamran E; Liu A; Mancini J; Neish D; Pakseresht A; Power GS; Christensen RAG
    Obes Sci Pract; 2020 Aug; 6(4):439-444. PubMed ID: 32874678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sex-Differences in Response to Treatment with Liraglutide 3.0 mg.
    Milani I; Guarisco G; Chinucci M; Gaita C; Leonetti F; Capoccia D
    J Clin Med; 2024 Jun; 13(12):. PubMed ID: 38929898
    [No Abstract]   [Full Text] [Related]  

  • 40. Efficacy and safety of dapagliflozin and liraglutide in patients with type 2 diabetes mellitus and newly diagnosed as overweight/obese.
    Liang YL; Chen L; Wang T; Qu JC
    Asian J Surg; 2023 Feb; 46(2):1000-1001. PubMed ID: 35963674
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.